Cargando…

A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters

The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to dramatic economic and health burdens. Although the worldwide SARS-CoV-2 vaccination campaign has begun, exploration of other vaccine candidates is needed due...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Mijia, Zhang, Yuexiu, Dravid, Piyush, Li, Anzhong, Zeng, Cong, KC, Mahesh, Trivedi, Sheetal, Sharma, Himanshu, Chaiwatpongsakorn, Supranee, Zani, Ashley, Kenney, Adam, Cai, Chuanxi, Ye, Chengjin, Liang, Xueya, Qiu, Jianming, Martinez-Sobrido, Luis, Yount, Jacob S., Boyaka, Prosper N., Liu, Shan-Lu, Peeples, Mark E., Kapoor, Amit, Li, Jianrong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Vaccines and Antiviral Agents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475528/ https://www.ncbi.nlm.nih.gov/pubmed/34379509 http://dx.doi.org/10.1128/JVI.00592-21

Ejemplares similares

HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV
por: Milewska, Aleksandra, et al.
Publicado: (2021)

Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques
por: Yu, Jingyou, et al.
Publicado: (2022)

A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern In Vitro and In Vivo
por: Chiem, Kevin, et al.
Publicado: (2021)

Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo
por: Weston, Stuart, et al.
Publicado: (2020)

SARS-CoV-2 and Influenza A Virus Coinfections in Ferrets
por: Huang, Ying, et al.
Publicado: (2022)

Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants
por: Bi, Wenwen, et al.
Publicado: (2022)

Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants
por: Acharya, Arpan, et al.
Publicado: (2021)

Comparison of Subgenomic and Total RNA in SARS-CoV-2-Challenged Rhesus Macaques
por: Dagotto, Gabriel, et al.
Publicado: (2021)

Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein
por: Chen, Yuliu, et al.
Publicado: (2022)

A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike
por: Lu, Mijia, et al.
Publicado: (2021)

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
por: Choi, Angela, et al.
Publicado: (2021)

A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice
por: Cao, Kangli, et al.
Publicado: (2022)

Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays
por: Yu, Jingyou, et al.
Publicado: (2021)

SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses
por: Carnell, George W., et al.
Publicado: (2021)

Stable Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen
por: Liu, Shufeng, et al.
Publicado: (2022)

A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection
por: Abdelnabi, Rana, et al.
Publicado: (2022)

Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants
por: Ishimaru, Hanako, et al.
Publicado: (2023)

Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants
por: Wu, Yan, et al.
Publicado: (2023)

Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2
por: Tostanoski, Lisa H., et al.
Publicado: (2021)

Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection
por: Jacob-Dolan, Catherine, et al.
Publicado: (2021)

A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice
por: Chaparian, Ryan R., et al.
Publicado: (2022)

Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines
por: Sun, Cong, et al.
Publicado: (2022)

Inactivated SARS-CoV-2 Vaccine Shows Cross-Protection against Bat SARS-Related Coronaviruses in Human ACE2 Transgenic Mice
por: Liu, Mei-Qin, et al.
Publicado: (2022)

Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity
por: Zhu, Yuanmei, et al.
Publicado: (2020)

Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL(pro) Reporter Assay
por: Froggatt, Heather M., et al.
Publicado: (2020)

Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
por: Ma, Huan, et al.
Publicado: (2021)

Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters
por: Takamatsu, Yuki, et al.
Publicado: (2022)

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
por: Yuan, Mengqi, et al.
Publicado: (2022)

The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells
por: Matsuyama, Shutoku, et al.
Publicado: (2020)

A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model
por: Ma, Jian, et al.
Publicado: (2023)

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants
por: Ferrari, Mathieu, et al.
Publicado: (2021)

Analysis of B Cell Receptor Repertoires Reveals Key Signatures of the Systemic B Cell Response after SARS-CoV-2 Infection
por: Zhang, Yudi, et al.
Publicado: (2022)

Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer
por: Zhan, Wuqiang, et al.
Publicado: (2022)

A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection
por: Ao, Zhujun, et al.
Publicado: (2022)

SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern
por: Lu, Mijia, et al.
Publicado: (2022)

Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects
por: Lusvarghi, Sabrina, et al.
Publicado: (2022)

Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection
por: Shi, Juan, et al.
Publicado: (2022)

A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL(pro) Inhibitor PF-00835231 as a Potential New Treatment for COVID-19
por: de Vries, Maren, et al.
Publicado: (2021)

Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease
por: Deschambault, Yvon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qrf9toa6sbi86k31qduo67qof9